Strike the dilemma of "no medicine", independent research and development of potential new drugs bring advanced pancreatic cancer second -line treatment "China Plan"

One of the three top tumors in the world, one of the three top tumor scholars in the 2022 European Cancer Internal Science Society (ESMO) Conference on September 9, local time in Paris, France. On September 10th, the digestive system tumor was held on September 10. Shanghai Jiaotong University Professor Wang Liwei, director of the Department of Oncology, Affiliated to the Medical College, brought a research on the ESMO international stage. The study is the first clinical study of the Ilideye Development Lipstick Injection of Ilideyin Decoction in the Chinese population combined with 5-FU/LV second-line two-line two-line two-line treatment of advanced pancreatic cancer and obtaining positive results.

The pancreatic tube adenocarcinoma is a common highly malignant tumor. The Globocan database of the International Cancer Research Agency (IARC) of the WHO shows that in 2020 pancreatic cancer has nearly 500,000 new cases worldwide, and about 120,000 new cases in China in China Cases account for about 25%of the world, which has a huge burden on the health and life of the people.

Due to the concealment of pancreatic cancer, the staging of the diagnosis is often late. The treatment mainly depends on the treatment of drugs. However, the current standard treatment plan for pancreatic cancer is very limited. In addition to the selection of the first-line therapy, the unused Jesitabine is based on or 5-FU as the basis The plan is almost faced with the dilemma of "useless use".

The HR-IRI-APC Studies were led by Professor Qin Shuyi of the Eastern Theater General Hospital and Professor Wang Liwei of Renji Hospital. It is a national multi-centered, random, double-blind, and control phase III clinical study. Study explores HR070803 (Ilideylidine hydrochloride) combined with fluoropicidine (5-FU)/sub-folic acid (LV) scheme for first-line Geshabinbari treatment. ) The efficacy and safety.

Study in a total of 298 patients with local advanced or advanced pancreatic cancer patients with failure to treat the treatment failed. Study 1: 1 randomly entered the group and received HR070803+5-FU/LV scheme or placebo+5-FU/LV scheme for the disease until the disease was ill until the disease Progress or intolerance. The main research finals are the total survival period (OS), and the secondary research end points include non -progressive survival (PFS), objective relief rate (ORR), safety, etc.

The results of the study show that the HR070803 combined with the 5-FU/LV scheme for the first-line Giscitabine treatment fails to remove the LAPC or MPC compared to the comfort group. VS.1.48 months), significantly reduced the risk of disease death and progress.

The choice of second -line treatment of pancreatic cancer is very limited. Domestic drug clinical research shows the glory. HR070803, as the first drug to develop phase III clinical research on Phase III clinical research, shows good anti -tumor activity and in the study. Safety is expected to become a standard treatment plan for the second -line treatment of advanced pancreatic cancer, bringing new choices to Chinese pancreatic cancer patients.

Author: Tang Wenjia

Edit: Tang Wenjia

Editor in charge: Jiang Peng

- END -